Review Article

Behaviour of Human Erythrocyte Aggregation in Presence of Autologous Lipoproteins

C. Saldanha,[1] J. Loureiro,[2] C. Moreira,[3] and J. Martins e Silva[4]

[1] *Instituto de Medicina Molecular, Unidade de Biologia Microvascular e Inflamação,*
 Instituto de Bioquímica Faculdade de Medicina da Universidade de Lisboa. Av Prof. Egas Moniz, 1649-028 Lisboa, Portugal
[2] *Departmento de Cardiologia, Hospital Fernando da Fonseca. IC19, 2720-276 Amadora, Portugal*
[3] *Departmento de Medicina I, Faculdade de Medicina da Universidade de Lisboa. Av Prof. Egas Moniz, 1649-028 Lisboa, Portugal*
[4] *Instituto de Biopatologia Química Faculdade de Medicina da Universidade de Lisboa. Av Prof. Egas Moniz, 1649-028 Lisboa, Portugal*

Correspondence should be addressed to C. Saldanha, carlotasaldanha@fm.ul.pt

The aim of this work was to evaluate *in vitro* the effect of autologous plasma lipoprotein subfractions on erythrocyte tendency to aggregate. Aliquots of human blood samples were enriched or not (control) with their own HDL-C, LDL-C, or VLDL-C fractions obtained from the same batch by density gradient ultracentrifugation. Plasma osmolality and erythrocyte aggregation index (EAI) were determined. Blood aliquots enriched with LDL-C and HDL-C showed significant higher EAI than untreated aliquots, whereas enrichment with VLDL-C does not induce significant EAI changes. For the same range of lipoprotein concentrations expressed as percentage of osmolality variation, the EAI variation was positive and higher in presence of HDL-C than upon enrichment with LDL-C ($P < 0.01$). Particle size, up to LDL diameter values, seems to reinforce erythrocyte tendency to aggregate at the same plasma osmolality (particle number) range of values.

1. Introduction

There is scientific agreement that a high serum level of low-density lipoproteins cholesterol (LDL-C) is a risk factor for atherosclerosis and cardiovascular diseases [1–3]. A linear relationship between LDL-C levels and the occurrence of coronary artery disease is well documented in two meta-analysis [4, 5]. Conversely, it has been shown that HDL-C when at normal or high serum levels acts as a vascular protector and consequently without contribution such as a risk factor for atherosclerosis [6]. However, if its antioxidant capacity is diminished in patients with systolic heart failure, it will predict a higher risk of incident long term for adverse cardiac events [7].

Several clinical studies evidenced associations between complex lipid macromolecules; for example, high LDL-C concentrations and blood rheological behaviour, like blood hyperviscosity, that are both referred to as cardiovascular risk factors [8–10]. Blood viscosity is dependent on macro-(hematocrit and plasma viscosity) and micro-(erythrocyte deformability and aggregation) hemorheological parameters. Disturbances in blood rheological behaviour, such as high values of the blood and plasma viscosity and increased erythrocyte aggregation tendency, have been described in patients with ischemic heart diseases [11]. Red blood cells (RBCs) participate in acute coronary occlusion, mainly under conditions of lower shear rate, for example, within the microcirculation in the peri-infarct domain of myocardium [12].

Under *in vitro* stasis conditions, RBCs in normal human blood form loose aggregates with a characteristic morphology, similar to a stack of coins. Such aggregation is frequently named as rouleaux formation [13]. After prolonged stases, individual rouleaux can cluster, thereby forming three-dimensional structures, [14, 15]. Under circulation, the attractive forces involved are relatively weak, and aggregates can be dispersed during flow by the shear rate [16]. RBCs aggregation increasing at low shear rate affects blood viscosity and microvascular flow dynamics being markedly enhanced in several clinical states [17–21].

Factors influencing RBCs aggregation can be divided into (i) extrinsic factors such as levels of plasma proteins (e.g., fibrinogen, lipoproteins, macroglobulins, or immunoglobulins), hematocrit, and shear rate, and (ii) intrinsic factors, for example, RBCs shape, deformability and membrane surface properties [22–32]. RBC membrane surface properties and structure, such as surface charge and the ability of macromolecules to penetrate the membrane glycocalyx, greatly affect aggregation for cells suspended in a defined medium [33, 34]. Different studies have shown that hyperlipoproteinemia is associated with erythrocyte hyperaggregation [35–37]. The inverse correlation of erythrocyte aggregation with HDL2-C subfraction was reported in hypercholesterolemia middle-aged male population without apparent symptoms of cardiovascular disease [38]. It was evidenced *in vitro* that LDL-C enhances the RBCs aggregation induced by fibrinogen according to two aggregation models [39]. Considering the particle-like nature of the lipoproteins we raise the hypothesis that increased amounts of lipoprotein particles may change plasma osmolality with repercussions in erythrocyte aggregation.

The aim of our work was to study *in vitro* the erythrocyte aggregation tendency in blood samples collected from healthy male adults and enriched with their own plasma lipoproteins subfractions.

2. Material and Methods

2.1. Blood Samples. On consecutive days, venous blood samples were obtained with previous consent from healthy fasting volunteers adult males ($n = 10$) after 15 min in the recumbent position and collected (for two plastic tubes) with anticoagulant (10 I.U. of heparin/mL or 0.1% EDTA).

2.2. Lipoprotein Fractions. Lipoproteins fractions were prepared by a discontinuous NaCl/KBr density gradient ultracentrifugation using an SW 50.1 rotor (Beckman) [40]. Lipoprotein fractions were characterised by electrophoresis (Electra HR Helena Laboratories) buffer tris-barbital-sodium buffer pH 8.8) in cellulose acetate by comparison with serum controls (Lipotrol, Helena Laboratories).

2.3. Erythrocyte Aggregation Index. Erythrocyte aggregation was determined using the MA1 aggregometer from Myrenne GMBH (Roetgen, Germany). The MA1 aggregometer consists of a rotating cone plate chamber which disperses the sample by high shear rate of $600\,s^{-1}$ and a photometer that determines the extent of aggregation. The intensity of light (emitted by a light emitting diode) is measured after transmission through the blood sample. The aggregation was determined in stasis for 10 seconds after dispersion of the blood sample [41].

2.4. Plasma Osmolality. Plasma osmolality was determined with the Osmomat 030 Cryoscopic Osmometer from Gonotec (Berlin, Germany).

2.5. Experimental Design. Blood samples from each donor were divided on aliquots, and after centrifugation and small volumes of plasma (0, 5 μL, 10 μL, 20 μL, and 40 μL) were discharged and replaced by equal values of their own previously enriched lipoprotein subfractions prepared a day before. With this procedure, no hematocrit variations were obtained. Blood aliquots were gently mixed by inversion, and erythrocyte aggregation was assessed. At the end of each assay, the aliquots were centrifuged at 12000 rpm for 1 minute in the Biofuge 15 centrifuge from Heraeus, and plasma osmolality was determined. HDL-C, LDL-C, and VLDL-C concentrations were expressed as percentage of osmolality variation values.

2.6. Statistical Analysis. The statistical evaluation performed utilized the "one-way" ANOVA with homogeneity test, cluster analysis, and average method.

3. Results

The major plasma lipoprotein subfractions were obtained by the discontinuous density gradient centrifugation between the density range of 1.006 and 1.300 g/mL. Each lipoprotein fraction was well banded with VLDL-C at the top, LDL-C in the upper middle and the HDL-C in the lower middle portion of the tube. After that, each fraction was pooled and submitted to electrophoresis where their obtained migration was confirmed by comparison with the serum control.

The volume of each lipoprotein sub-fraction added to the autologous blood samples aliquots caused variation of osmolality concentrations in relation to its absence. Using the cluster analysis and the beverage method, four classes of concentration range expressed as osmolality variation were grouped for each LDL-C; the VLDL-C and the HDL-C enriched blood aliquots, namely, Class I 0.005–0.025; Class II 0.030–0.035; Class III 0.045–0.055; Class IV 0.077–0.095 (Figure 1).

The erythrocyte aggregation variation for each enriched LDL, HDL, and VLDL blood aliquots in relation to the initial value is grouped by the different osmolality class variation values (Figure 2). The variation of erythrocyte aggregation in relation to the initial values depends on the plasma osmolality values, as well as of the type of lipoprotein sub-fraction. The enriched VLDL-C blood samples aliquots do not induce statistical significant variation on erythrocyte aggregation values (Figure 3). At variance in relation to the initial erythrocyte aggregation values, the enriched LDL-C blood samples presented significant statistical enhanced values at all range of percentage of osmolality variation (Figure 4). The same behaviour was verified in the enriched HDL-C blood aliquots, with exception for the higher values of percentages of osmolality variation, where a very significant ($P < 0.0001$) decrease was obtained for the erythrocyte aggregation (Figure 5). For the same range of osmolality variation, the two types of lipoproteins LDL-C and HDL-C induced different variation of erythrocyte aggregation ($P < 0.01$). When the values of osmolality variation were plotted against the respective values of aggregation variation

FIGURE 1: Histogram presenting the concentrations of enriched blood samples with LDL-C (red), HDL-C (blue), VLDL-C (green) distributed by four classes according the osmolality scale of values (class I 0.005–0.025; class II 0.030–0.035: class III 0.045–0.055; class IV 0.077–0.095).


FIGURE 2: Histogram presenting the values of the erythrocyte aggregation variation obtained in enriched blood samples with LDL-C (red), HDL-C (blue), VLDL-C (green) in the four classes of concentration according the osmolality scale of values (I 0.005–0.025; II 0.030–0.035: III 0.045–0.055; IV 0.077–0.095).

obtained in each enriched HDL-C aliquot, a significant ($R^2 = 0.383$) inverse linear regression was obtained (Figure 6).

4. Discussion

In the present *in vitro* study, we investigated the induction of human erythrocyte tendency to aggregation by autologous lipoproteins sub-fractions. With the amount of lipoprotein


FIGURE 3: Values of erythrocyte aggregation index (mean +/– sd) obtained in enriched blood samples with HDL-C and without enrichment.

*Vs 0—$P < 0.01$
**Vs 5—$P < 0.001$

FIGURE 4: Values of erythrocyte aggregation index (mean +/– sd) obtained in enriched blood samples with HDL-C and without enrichment

sub-fractions added, changes in plasma osmolality were observed as a consequence of the increase number of particles. We used cluster method on the values of osmolality to define four classes (Figure 1).

In blood aliquots enriched with VLDL-C, no changes in erythrocyte aggregation index were verified (Figure 3). For the same amount of particles corresponding to the same class of osmolality variation, both HDL-C and LDL-C enrichment induce enhancement of erythrocyte aggregation (Figures 4 and 5). VLDL has higher diameter than the other two lipoprotein classes [42] and may either rest in the plasma bulk not interfering with erythrocyte aggregation tendency. LDL-C particles bind in a nonabsolute specific way with erythrocyte membrane, while 60% of membrane area can be occupied by HDL-C as has been described [43]. The occupancy of some areas of erythrocyte membrane by HDL-C or LDL-C, causing some interference in the promotion of EAI tendency, may be an explanation for our results. Significant ($P < 0.01$) higher values of erythrocyte aggregation were obtained in HDL-C-enriched aliquots more than for LDL-C-enriched ones at the same class of osmolality variation (under the same number of particles). The exception was

*Vs 0 —$P < 0.01$
**Vs 20—$P < 0.001$

Figure 5: Values of erythrocyte aggregation index (mean +/− sd) obtained in enriched blood samples with LDL-C and without enrichment.


R^2 linear = 0.383

Figure 6: Presentation of the association obtained between the erythrocyte aggregation values and the osmolality values in enriched blood sample with HDL-C.

for the HDL-C-enriched aliquots with the highest percentage of osmolality variation which significantly ($P < 0.0001$) decreased EAI to lower values than the aliquot control obtained. We raise the hypothesis that the higher number of unbinding HDL-C particles may increase the ionic strength to a threshold and consequently pull away the erythrocytes decreasing their tendency to aggregate.

Our results suggest that in healthy human blood aliquots enriched with autologous HDL-C or LDL-C, (where fibrinogen is present at normal range), when submitted to shear rate to disaggregate RBCs, and stopped after that, EAI tendency increases. The association between EAI values and HDL-C obtained in our experimental design is in accordance with others studies [39], which is a decrease of fibrinogen-induced

RBCs aggregation in presence of the HDL2 subclass as not observed in a different experimental approach.

Recently [44], it was verified that the LDL particles number must be considered as an indicator for atherosclerosis risk factor, which has been previously remembered by others in the prevention of cardiovascular disease [45].

Two models, the cross-bridging and the depletion layer, were described to explain the reversible erythrocyte aggregation process at physiological conditions [46], but there are controversies and difficulties to adopt one or reject another. The depletion model developed for polymer solutions of dextran demonstrated that there is an optimal molecular weight value to reach the greater erythrocyte aggregation tendency [47]. The hydrodynamic radius (Rh) determined for VLDL [48] is in the range between 15 nm and 40 nm which is much above of others belonging to macromolecules promoters of erythrocyte aggregation increase [49]. Particle size is an influent factor that may explain the absence of VLDL effect in the erythrocyte aggregation obtained. Regarding our results, they may also fit the cross-bridging model if, by an unknown mechanism, we assume that the particles numbers and size favour fibrinogen binding in a similar way as previously reported for immunoglobulin effects on fibrinogen-mediated erythrocyte aggregation [50, 51]. More studies are needed to explain in what model fit the effects of lipoproteins in erythrocyte aggregation. Our results may contribute to better understand the direct associations between high erythrocyte aggregation tendency and other cardiovascular risk factors such as hyperlipoproteinemia.

Acknowledgments

References

[1] W. B. Kannel, W. P. Castelli, and T. Gordon, "Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham study," *Annals of Internal Medicine*, vol. 90, no. 1, pp. 85–91, 1979.

[2] N. E. Miller, F. Hammett, S. Saltissi, H. Vanzeller, S. Coltart, and B. Lewis, "Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins," *The British Medical Journal*, vol. 282, no. 6278, pp. 1741–1744, 1981.

[3] A. M. Alshehri, "Metabolic syndrome and cardiovascular risk," *Journal of Family and Community Medicine*, vol. 17, pp. 73–78, 2010.

[4] C. Baigent, A. Keech, P. M. Kearney, L. Blackwell, and G. Buck, "Efficacy and safety of cholesterol-lowering treatment prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins," *The Lancet*, vol. 366, pp. 1267–1278, 2005.

[5] J. G. Robinson, B. Smith, N. Maheshwari, and H. Schrott, "Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis," *Journal of the American College of Cardiology*, vol. 46, no. 10, pp. 1855–1862, 2005.

[6] A. V. Khera, M. Cuchel, M. de la Llera-Moya et al., "Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis," *The New England Journal of Medicine*, vol. 364, no. 2, pp. 127–135, 2011.

[7] W. H. Tang, Y. Wu, S. Mann et al., "Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure," *Circulation—Heart Failure*, vol. 4, no. 1, pp. 59–64, 2011.

[8] A. H. Seplowitz, S. Chien, and F. R. Smith, "Effects of lipoproteins on plasma viscosity," *Atherosclerosis*, vol. 38, no. 1-2, pp. 89–95, 1981.

[9] G. Lowe, "Blood viscosity, lipoproteins, and cardiovascular risk," *Circulation*, vol. 85, no. 6, pp. 2329–2331, 1992.

[10] W. Koenig, M. Sund, E. Ernst, W. Mraz, V. Hombach, and U. Keil, "Association between rheology and components of lipoproteins in human blood: results from the MONICA project," *Circulation*, vol. 85, no. 6, pp. 2197–2204, 1992.

[11] G. Kesmarky, K. Toth, L. Habon, G. Vajda, and I. Juricskay, "Hemorheological parameters in coronary artery disease," *Clinical Hemorheology and Microcirculation*, vol. 18, no. 4, pp. 245–251, 1998.

[12] J. Dormandy, E. Ernst, A. Matrai, and P. T. Flute, "Hemorheologic changes following acute myocardial infarction," *The American Heart Journal*, vol. 104, no. 6, pp. 1364–1367, 1982.

[13] A. M. Ehrly, *Therapeutic Hemorheology*, Springer, New York, NY, USA, 1991.

[14] G. D. O. Lowe, *Clinical Blood Rheology*, CRC Press, Boca Raton, Fla, USA, 1988.

[15] J. F. Stoltz, M. Singh, and P. Riha, *Hemorheology in Practice*, IOS Press, Amsterdam, The Netherlands, 1999.

[16] O. K. Baskurtand and H. J. Meiselman, "Cellular determinants of low-shear blood viscosity," *Biorheology*, vol. 34, no. 3, pp. 235–247, 1997.

[17] P. Sousa-Ramalho, R. Martins, C. Saldanha, L. Cardoso, D. Santos, and J. Martins e Silva, "Haemorheological changes in glaucoma," *New Trends in Ophthalmology*, vol. 1, pp. 45–51, 1986.

[18] S. Chien and L. A. Lang, "Physicochemical basis and clinical implications of red cell aggregation," *Clinical Hemorheology*, vol. 7, no. 1, pp. 71–91, 1987.

[19] P. Souza-Ramalho, H. Hormigo, R. Martins, C. Saldanha, and J. Martins e Silva, "Haematological changes in retinal vasculitis," *Eye*, vol. 2, no. 3, pp. 278–282, 1988.

[20] L. Sargento, L. Zabala, T. Gomes, C. Saldanha, J. Martins-Silva, and P. Souza-Ramalho, "The effect of angiography with disodium fluorecein on the hemorheologic parametes of diabetes," *Acta Médica Portuguesa*, vol. 9, pp. 303–307, 1996.

[21] E. Konstantinova, L. Ivanova, T. Tolstaya, and E. Mironova, "Rheological properties of blood and parameters of platelets aggregation in arterial hypertension," *Clinical Hemorheology and Microcirculation*, vol. 35, no. 1-2, pp. 135–138, 2006.

[22] T. Shiga, N. Maeda, and K. Kon, "Erythrocyte rheology," *Critical Reviews in Oncology/Hematology*, vol. 10, no. 1, pp. 9–48, 1990.

[23] N. Maeda, M. Seike, Y. Suzuki, and T. Shiga, "Effect of pH on the velocity of erythrocyte aggregation," *Biorheology*, vol. 25, no. 1-2, pp. 25–30, 1988.

[24] G. Yardin and H. J. Meiselman, "Effects of cellular morphology on the viscoelastic behavior of high hematocrit RBC suspensions," *Biorheology*, vol. 26, no. 2, pp. 153–175, 1989.

[25] C. Saldanha and J. Martins e Silva, "Effect of plasma osmolality on erythrocyte aggregation index. Hémorheologie et aggregation erythrocytaire," in *Théories et Applications Cliniques*,

J. F. Stoltz, M. Donner, and A. L. Copley, Eds., vol. 3, pp. 142–145, Editions Medicales Internationales, 1991.

[26] R. Mesquita, M. I. Gonçalves, S. Dias, L. Sargento, C. Saldanha, and J. Martins e Silva, "Ethanol and erythrocyte membrane interaction: a hemorheologic perspective," *Clinical Hemorheology and Microcirculation*, vol. 21, no. 2, pp. 95–98, 1999.

[27] I. Gonçalves, C. Saldanha, and J. Martins e Silva, "Beta-estradiol effects on erythrocyte aggregation—a controlled in vitro study," *Clinical Hemorheology and Microcirculation*, vol. 25, no. 3-4, pp. 127–134, 2001.

[28] R. Mesquita, I. Pires, C. Saldanha, and J. Martins-Silva, "Effects of acetylcholine and spermineNONOate on erythrocyte hemorheologic and oxygen carrying properties," *Clinical Hemorheology and Microcirculation*, vol. 25, no. 3-4, pp. 153–163, 2001.

[29] T. Santos, R. Mesquita, J. Martins e Silva, and C. Saldanha, "Effects of choline on hemorheological properties and NO metabolism of human erythrocytes," *Clinical Hemorheology and Microcirculation*, vol. 29, no. 1, pp. 41–51, 2003.

[30] S. Hilário, C. Saldanha, and J. Martins e Silva, "An in vitro study of adrenaline effect on human erythrocyte properties in both gender," *Clinical Hemorheology and Microcirculation*, vol. 28, no. 2, pp. 89–98, 2003.

[31] F. A. Carvalho, A. V. Maria, J. M. Braz Nogueira, J. Guerra, J. Martins-Silva, and C. Saldanha, "The relation between the erythrocyte nitric oxide and hemorheological parameters," *Clinical Hemorheology and Microcirculation*, vol. 35, no. 1-2, pp. 341–347, 2006.

[32] J. P. Almeida, F. A. Carvalho, T. Freitas, and C. Saldanha, "Modulation of hemorheological parameters by the erythrocyte redox thiol status," *Clinical Hemorheology and Microcirculation*, vol. 40, no. 2, pp. 99–111, 2008.

[33] M. W. Rampling, H. J. Meiselman, B. Neu, and O. K. Baskurt, "Influence of cell-specific factors on red blood cell aggregation," *Biorheology*, vol. 41, no. 2, pp. 91–112, 2004.

[34] V. Schechner, I. Shapira, S. Berliner et al., "Significant dominance of fibrinogen over immunoglobulins, C-reactive protein, cholesterol and triglycerides in maintaining increased red blood cell adhesiveness/aggregation in the peripheral venous blood: a model in hypercholesterolaemic patients," *The European Journal of Clinical Investigation*, vol. 33, no. 11, pp. 955–961, 2003.

[35] R. H. Jay, M. W. Rampling, and D. J. Betteridge, "Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment," *Atherosclerosis*, vol. 85, no. 2-3, pp. 249–256, 1990.

[36] S. Muller, O. Ziegler, M. Donner, P. Drouin, and J. F. Stoltz, "Rheological properties and membrane fluidity of red blood cells and platelets in primary hyperlipoproteinemia," *Atherosclerosis*, vol. 83, no. 2-3, pp. 231–237, 1990.

[37] A. Vayá, M. Martínez, R. Carmena, and J. Aznar, "The lipid composition of red blood cells and their hemorheological behaviour in patients with primary hyperlipoproteinemia," *Clinical Hemorheology and Microcirculation*, vol. 13, pp. 447–457, 1993.

[38] S. M. Razavian, V. Atger, P. Giral et al., "Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemic men," *Arteriosclerosis and Thrombosis*, vol. 14, no. 3, pp. 361–366, 1994.

[39] E. Simon, S. M. Razavian, J. L. Beyec et al., "Influence of lipoprotein subfractions on dextran- and fibrinogen-induced erythrocyte aggregation," *Clinical Hemorheology*, vol. 15, no. 4, pp. 667–676, 1995.

[40] B. H. Chung, T. Wilkinson, J. C. Geer, and J. P. Segrest, "Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor," *Journal of Lipid Research*, vol. 21, no. 3, pp. 284–291, 1980.

[41] H. Schmid-Schonbein, E. Volger, P. Teitel, H. Kieswetter, V. Dauer, and L. Heilman, "New hemorheological techniques for the routine laboratory," *Clinical Hemorheology*, vol. 2, no. 1-2, pp. 93–105, 1982.

[42] A. M. Gotto Jr., H. J. Pownall, and R. J. Havel, "Introduction to the plasma lipoproteins," *Methods in Enzymology*, vol. 128, pp. 3–41, 1986.

[43] D. Y. Hui, J. G. Noel, and J. A. Harmony, "Binding of plasma low density lipoproteins to erythrocytes," *Biochimica et Biophysica Acta*, vol. 664, no. 3, pp. 513–526, 1981.

[44] J. D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R. H. MacKey, and D. C. Goff, "Clinical implications of discordance between low-density lipoprotein cholesterol and particle number," *Journal of Clinical Lipidology*, vol. 5, no. 2, pp. 105–113, 2011.

[45] W. C. Cromwell, J. D. Otvos, M. J. Keyes et al., "LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—implications for LDL management," *Journal of Clinical Lipidology*, vol. 1, no. 6, pp. 583–592, 2007.

[46] H. J. Meiselman, B. Neu, M. W. Rampling, and O. K. Baskurt, "RBC aggregation: laboratory data and models," *The Indian Journal of Experimental Biology*, vol. 45, no. 1, pp. 9–17, 2007.

[47] B. Neu, R. Wenby, and H. J. Meiselman, "Effects of dextran molecular weight on red blood cell aggregation," *Biophysical Journal*, vol. 95, no. 6, pp. 3059–3065, 2008.

[48] D. C. Rambaldi, A. Zattoni, S. Casolari, P. Reschiglian, D. Roessner, and C. Johann, "An analytical method for size and shape characterization of blood lipoproteins," *Clinical Chemistry*, vol. 53, no. 11, pp. 2026–2029, 2007.

[49] K. J. Armstrong, R. B. Wenby, H. J. Meiselman, and T. C. Fisher, "The hydrodynamic radii of macromolecules and their effect on red blood cell aggregation," *Biophysical Journal*, vol. 87, no. 6, pp. 4259–4270, 2004.

[50] N. Maeda and T. Shiga, "Opposite effect of albumin on the erythrocyte aggregation induced by immunoglobulin G and fibrinogen," *Biochimica et Biophysica Acta*, vol. 855, no. 1, pp. 127–135, 1986.

[51] R. Ben-Ami, G. Barshtein, T. Mardi et al., "A synergistic effect of albumin and fibrinogen on immunoglobulin-induced red blood cell aggregation," *The American Journal of Physiology— Heart and Circulatory Physiology*, vol. 285, pp. H2663–H2669, 2003.